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Abstract: Fructose 1,6-bisphosphatase (FBPase) has been identified as a drug discovery 
target for lowering  glucose in type 2 diabetes  mellitus.  In this study,  a large series of  
105  FBPase  inhibitors  were  studied  using  a  combinational  method  by  3D-QSAR, 
molecular  docking  and  molecular  dynamics  simulations  for  a  further  improvement  in 
potency.  The  optimal  3D  models  exhibit  high  statistical  significance  of  the  results, 
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especially  for  the  CoMFA  results  with  rncv
2,  q
2  values  of  0.986,  0.514  for  internal 
validation, and rpred
2, rm
2 statistics of 0.902, 0.828 statistics for external validation. Graphic 
representation of the results, as contoured 3D coefficient plots, also provides a clue to the 
reasonable modification of molecules. (1) Substituents with a proper length and size at the 
C5 position of the thiazole core are required to enhance the potency; (2) A small and 
electron-withdrawing group at the C2 position linked to the thiazole core is likely to help 
increase the FBPase inhibition; (3) Substituent groups as hydrogen bond acceptors at the 
C2 position of the furan ring are favored. In addition, the agreement between 3D-QSAR, 
molecular  docking  and  molecular  dynamics  simulation  proves  the  rationality  of  the 
developed models. These results, we hope, may be helpful in designing novel and potential 
FBPase inhibitors. 
Keywords: 3D-QSAR; molecular dynamics; FBPase inhibitors; CoMFA; CoMSIA 
 
1. Introduction  
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder that results from defects in both 
insulin secretion and insulin action. Nowadays, T2DM, as a major health hazard, is widespread and 
sometimes even fatal, which leads to both medical and social challenges. It has been reported [1] that 
type  2  diabetes  mellitus  is  a  progressive  disorder.  Often  it  can  be  treated  initially  with  oral  drug 
monotherapy. However, with the progress of the disease it will require the addition of other oral drugs, 
and in many patients the therapy of injecting insulin will be critically required to achieve targeted 
glycemic levels. As we know, patients with diabetes experience significant morbidity and mortality 
from microvascular and macrovascular complications.  It has been documented that diabetes is the 
primary  cause of blindness [2]. Therefore, patients with diabetes and corresponding complications 
suffer  from  great  mental  and  physical  pain.  It  is  imperative  for  researchers  to  develop  safe  and 
effective drugs to prevent this kind of obstinate disease. Currently, many reports have illustrated that 
diet  and  exercise  therapy  plays  an  important  role  in  the  treatment  for  patients  with  T2DM  [3,4]. 
However,  if  this  therapy  fails  to  achieve  the  desired  level  of  glycemic  control,  pharmacologic 
intervention  is  required.  Now,  several  classes  of  oral  drugs  are  reported  to  have  an  effect  on  the 
treatment of T2DM including sulfonylureas [5], metformin [6], repaglinide [7], troglitazone [8] and so 
on. However, these oral agents still have some limitations. For example, sulfonylurea therapy usually 
is associated with weight gain, which has been implicated as a reason of secondary drug failure [3]; 
Metformin therapy is forbidden in patients with renal and hepatic disease, respiratory insufficiency and 
alcohol abuse; and troglitazone, a very expensive oral drug, often causes hypercholesterolemia which 
is a major risk factor for coronary artery disease. Therefore, the development of a kind of drug with 
more safe profiles and less side effects is a task of top priority. 
Most of the work has focused on enzymes in the gluconeogenesis (GNG) pathway, because this 
pathway is partly responsible for the excessive glucose production in type 2 diabetes mellitus [9]. Out 
of these enzymes, fructose 1,6-bisphosphatase (FBPase), a highly regulated enzyme that catalyzes the 
second to last step in gluconeogenesis [10,11], draws the attractiveness as a drug target to treat T2DM. Int. J. Mol. Sci. 2011, 12                       
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FBPase  enables  the  inhibition  of  gluconeogenesis  from  all  GNG  substrates  while  avoiding  direct 
effects  on  glycogenolysis,  glycolysis  and  the  tricarboxylic  acid  cycle.  Moreover,  evidence  from 
clinical researches illustrates that FBPase inhibitors may show an adequate safety margin [11]. Thus, 
several classes of drugs targeting at the FBPase, recently, have been reported including MB06322 [12], 
anilinoquinazolines  [13],  benzoxazole  benzenesulfonamides  [14],  MDL-29951  [15],  AMP  
mimics [16–18], etc. However, among these agents, some series show very poor oral bioavailability 
(OBAV),  thus,  making  the  development  of  novel  drugs  with  acceptable  OBAV  and  more  
potency required. 
Nowadays, in silico modeling approaches [19–23], as a productive and cost-effective technology in 
design of novel lead compounds, have been used in combination with experimental practices [24–27] 
to  facilitate  the  drug  discovery  process.  In  view  of  this,  Chen  and  co-workers  have  carried  out 
excellent  work  to  study  the  FBPase  inhibitors  using  the  in  silico  method  based  on  63  FBPase  
inhibitors [28]. In the present work, more diverse set of molecules were performed to examine if a 
similar level of prediction can be achieved. In addition, besides both three-dimensional quantitative 
structural  activity  relationships  (3D-QSAR)  and  molecular  docking,  in  this  work,  a  molecular 
dynamics (MD) approaches were also performed to investigate the stability of the docking results. 
Thus in the present work, a total of 105 thiazoles and oxazole-based inhibitors of FBPase was collected 
to build 3D-QSAR models using comparative molecular field analysis (CoMFA) [29] and comparative 
molecular similarity indices analysis (CoMSIA) methods [30]. The reliability and robustness of the 
developed  best  models  were  estimated  with  bootstrapping  analysis  and  y-randomization  check.  In 
addition, the predictive abilities of the obtained models were validated statistically with an external test 
set of compounds using multiple statistical criteria. In addition, a combined computational approach 
including  the  docking  analysis  and  molecular  dynamics  (MD)  simulation  was  also  employed  to 
elucidate the probable binding modes of these antagonists at the binding site of the FBPase. The good 
concordance  between  the  3D  contour  maps  and  the  docking  result  provides  our  identification  of 
several key features of the binding mechanism for these inhibitors. We hope the developed models 
could provide some meaningful clues in the future synthesis of highly potent and orally bioavailable 
FBPase inhibitors. 
2. Results and Discussion  
2.1. Molecular Docking 
The docking results could illustrate to us the active-site architecture and ligand binding model as 
well as the network of electrostatic, hydrogen bond and van der Waals interactions associated with 
ligand binding between the inhibitors and FBPase. In this work, the most potent compound 27 is taken 
as the representative to elucidate this point in detail. As illustrated in Figure 1, compound 27 locates at 
the active site of the enzyme and binds primarily through the H-bond and van der Waals interactions. 
The  majority  of  hydrogen-bond  and  hydrophobic  modes  are  the  same  as  those  observed  in  
the  crystal  structure  of  AMP  complexed  with  FBPase  [31],  which  validates  the  reliability  of  the  
docking model. Int. J. Mol. Sci. 2011, 12                       
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Figure  1.  The  binding  models  of  the  most  potent  compound  27  with  Fructose  
1,6-bisphosphatase (FBPase). Top panel: A surface rendering to illustrate the interactions 
between  compound  27  with  the  representative  key  amino  acids.  The  inhibitor  is 
represented  as  stick  model  and  carbon  atoms  are  colored  green.  Bottom  panel:  2D 
representation  of  compound  27  and  FBPase.  The  active  site  residues  are  represented  as 
follows: polar residues in purple, hydrophobic residues in olive, respectively. The red dash 
denotes H-bonds. 
 
As can be seen from the figure, the phosphate of compound 27 forms hydrogen bond interactions 
with the main chain NH group residues of Thr27, Glu29, Leu30, with the OH of Tyr113, Thr27, and 
the side chain NH
3+ group residue of Lys112. In addition, the amino group attached to the thiazole ring 
forms two other hydrogen bonds with the FBPase residues: one with the carbonyl O of Val17 and the 
other with the side chain OH of Thr31. Besides these hydrogen bond interactions, the van der Waals 
interactions also play a central role in the ligand binding as shown in Figure 1. The furan ring interacts 
with the main chain carbons of Gly26 and Gly28, with the side chain carbons of Leu30 and Val160. 
Interactions between the thiazole core and the binding pocket, besides hydrogen bond interactions, are 
mainly van der Waals contacts with the Phe16, Val17 and Met18. For the cyclohexyl ring, one can 
notice that the cyclohexyl ring produces van der Waals interactions with the amino residues of Ala24, 
Glu20,  Asp178,  Cys179  and  Met177.  All  these  interactions  fix  the  inhibitor  27  in  the  binding  
pocket steadily. 
Compared to the interactions between AMP and FBPase [31], the most potent compound 27 forms 
more van der Waals interactions with the amino residues of FBPase, which may be one possible reason 
exhibiting  its  high  activity.  Through  the  investigation  of  the  series  of  thiazoles  and  oxazoles,  an 
interesting  common  characteristic  was  observed  for  most  of  the  inhibitors  that  they  all  have  the 
phosphate group, as a hydrogen bond acceptor, which forms a hydrogen bond network with the amino 
residues of FBPase. Int. J. Mol. Sci. 2011, 12                       
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2.2. 3D-QSAR Statistical Results 
To measure the predictive capability of a QSAR model, several statistical parameters including 
especially the cross-validated correlation coefficient (q
2), non-cross-validated correlation coefficient 
(rncv
2), and standard error of estimate (SEE), F-statistic values, predicted correlation coefficient for the 
test set of compounds (rpred
2) as well as the principal components (PCs) were calculated. 
When building a 3D-QSAR model, two important elements impacting greatly on the quality of the 
model must be taken into account. One is the molecular alignment. In this work, both the ligand- and 
receptor-based alignment rules were applied, with the purpose to compare and implement the results of 
them for exploring the receptor-ligand interaction mechanism as really as possible. Another factor is 
the grid descriptors. Herein, two 3D descriptors for CoMFA (i.e., the steric and electrostatic fields) and 
five 3D descriptors for CoMSIA (i.e., the steric, electrostatic, hydrophobic, hydrogen bond (H-bond) 
donor and acceptor fields) as well as their 31 combinations were applied as the independent variables 
in the building models. 
As  a  result,  several  optimal  CoMFA  and  CoMSIA  models  with  proper  predictive  performance 
based  on  the  same  training  (77  molecules)  and  test  set  (28  molecules)  were  obtained,  with  their 
statistical results shown in Table 1. For the ligand-based study, the optimal CoMFA model employing 
both  the  steric  and  electrostatic  field  descriptors  obtains  a  LOO  cross-validated  q
2  of  0.514,  a 
correlation  coefficient  rncv
2  of  0.986,  a  SEE  value  of  0.108  and  an  F  value  of  462.072  using  
10 components, which indicates a good internal predictivity of the model. When being validated by the 
independent test set which is not included in the building of the model, an rpred
2 = 0.902 is achieved, 
proving its high external predictive power. As to the field contribution, the steric and electrostatic field 
descriptors account for 0.563 and 0.437, respectively, to the CoMFA model. 
During  the  ligand-based  CoMSIA  analysis,  the  model  with  slightly  worse  but  still  acceptable 
statistical performances (q
2 = 0.443, rncv
2 = 0.874, SEE = 0.314, F = 80.809) than that of the CoMFA 
one was observed, with three field descriptors (steric, electrostatic, hydrogen bond acceptor) employed. 
The rpred
2 value for the 28 test set compounds is 0.756. As to the relative contribution, the electrostatic 
field makes the greatest (0.453), followed by steric field (0.379), and the hydrogen bond acceptor field 
gives 0.168. 
For the receptor-based 3D-QSAR studies, it can be observed that no statistically acceptable results 
were obtained in terms of both internal and external validation criteria (Table 1). Thus, we focus on 
our further research to the optimal ligand-based CoMFA and CoMSIA models. Figure 2 illustrates the 
correlation plots of the experimental versus the predicted pIC50 values of the training (black dot) and 
test (red asterisk) sets for the two 3D-QSAR models. Clearly, good correlationships are observed since 
the  predicted  values  are  almost  as  accurate  as  the  experimental  activities  for  the  whole  dataset 
(especially for the CoMFA model). Table S1 (Supporting Information) lists the predicted results of the 
whole data set. Int. J. Mol. Sci. 2011, 12                       
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Table  1.  The optimal comparative molecular  field analysis (CoMFA)  and comparative 
molecular  similarity  indices  analysis  (CoMSIA)  results  based  on  different  
superimposition methods. 
PLS analysis 
Superimposition Methods 
I  II  III 
CoMFA  CoMSIA  CoMFA  CoMSIA  CoMFA  CoMSIA 
q
2  0.514  0.443  0.047  0.191  0.121  0.147 
PCs  10  6  2  2  4  2 
rncv
2  0.986  0.874  0.486  0.485  0.796  0.540 
SEE  0.108  0.314  0.617  0.618  0.394  0.584 
F value  462.072  80.809  35.010  34.859  70.348  43.425 
rbs
2
  0.992  0.905  0.635  0.601  0.875  0.630 
SEEbs  0.082  0.267  0.520  0.544  0.304  0.519 
rpred
2  0.902  0.756  0.364  0.559  0.352  0.473 
Relative Contribution (%) 
S  0.563  0.379  0.398  -  0.581  - 
E  0.437  0.453  0.602  0.479  0.419  - 
H  -  -  -  -  -  - 
D  -  -  -  0.521  -  0.822 
A  -  0.168  -  -  -  0.178 
q
2,  cross-validated  correlation  coefficient  after  the  leave-one-out  procedure;  PCs,  principal 
components;  rncv
2,  non-cross-validated  correlation  coefficient;  SEE,  standard  error  of  estimate;  
F, the value of F statistic; rbs
2, the average r
2 value from a bootstrapping analysis for 100 runs; 
SEEbs,  the  average  SEE  value  from  a  bootstrapping  analysis  for  100  runs;  rpred
2,  predicted 
correlation  coefficient  for  the  test  set  of  compounds.  Superimposition  method:  I,  from  the  
database  alignment;  II,  from  docking  alignment;  III,  from  database  alignment  based  on  the  
docking conformations. 
Figure  2.  The  predicted  versus  the  actual  pIC50  values  for  the  FBPase  inhibitors:  
(A) CoMFA model and (B) CoMSIA model. 
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Overfitting can be a problem in QSAR. One should demonstrate that the final model is based on the 
correct number of components. Herein, in order to address this problem, we have validated the optimal 
CoMFA  model  using  first  11  components  and  CoMSIA  model  using  first  7  components.  By 
investigating the q
2, rncv
2 and SEE, we have noticed the two optimal models improve with the addition 
of components, that 10 components are needed for the CoMFA model and 6 for the CoMSIA model 
and that further improvement is not obtained with additional components (see Tables S2 and S3). 
As a further test of the robustness of the CoMFA and CoMSIA models, we also randomized the 
target values for 50 times. As a result, none of obtained models have significant q
2. The q
2 values 
obtained are in the range from −0.630 to 0.085 for CoMFA, and from −0.476 to 0.013 for CoMSIA, 
respectively. This indicates that the q
2 values in both the optimal CoMFA and CoMSIA models with 
original data are not due to chance correlations. 
To testify firmly the good performance of the prediction, the squared correlation coefficient values 
between the actual and predicted values of the test set compounds with intercept (rtest
2) and without 
intercept (r0
2) are also calculated. Table 2 gives the values of the parameters for the optimal CoMFA 
and CoMSIA models in the present work. According to references [32–35], models are considered 
acceptable if they satisfy all following conditions: (1) rpred
2 > 0.5, (2) rtest
2 > 0.6, and (3) r0
2 is close to 
rtest
2, such that the (rtest
2 − r0
2)/rtest
2 < 0.1 and 0.85 ≤ k ≤ 1.15 or 0.85 ≤ k′ ≤ 1.15. When the observed 
values of the test set compounds (X axis) are plotted against the predicted values of the compounds  
(Y axis) setting intercept to zero, the slope of the fitted line gives the value of k. Interchange of the axes 
gives the value of k′. As can be seen from the table, both the best CoMFA and CoMSIA models 
successfully pass those tests. 
Table 2. Comparison of the external predictability of the optimal CoMFA and CoMSIA, 
for the prediction set. 
Model  rtest
2
  rpred
2
  r0
2
  (rtest
2 − r0
2)/rtest
2
  r
2
m
  k  k′
 
CoMFA  0.909  0.902  0.901  0.009  0.828  0.981  1.018 
CoMSIA  0.741  0.756  0.693  0.065  0.579  0.990  1.005 
rtest
2,  conventional  r
2
 in  the  test  set;  rpred
2,  predicted  correlation  coefficient  for  the  test  set  of 
compounds; r0
2, r
2 with the Y-intercept set to zero; k, slope of regression lines (observed versus 
predicted activities) through the origin; k′, slope of regression lines (predicted versus observed 
activities) through the origin. 
A previous report [36] has illustrated that the rpred
2 may not truly reflect the predictive capability of 
a model on a new dataset. Also, the squared regression coefficient (rtest
2) between the observed and 
predicted values of the test set compounds does not necessarily mean that the predicted values are very 
near to the observed activities (as there may be considerable numerical difference between the values 
though  maintaining  an  overall  good  inter-correlation).  To  better  evaluate  the  external  predictive 
capacity of a model a modified r
2 term (rm
2) is been defined as follows [37]: 
) 1 (
2 2 2 2
o test test m r r r r − − × =   (1) 
In case of good external prediction capacity, predicted values will be very close to the actual values 
and thus the rtest
2 value will be very near to the r0
2. In the best case rm
2 may be equal to rtest
2, whereas Int. J. Mol. Sci. 2011, 12                       
 
 
8168 
in the worst case rm
2 value could be zero. Herein, the rm
2 values of both the two models are larger than 
the
 recommended value (0.5). We also noticed that, by comparing the CoMFA with CoMSIA model, 
the former produces higher predictive power than the latter in terms of both the internal and external 
exams (Tables 1 and 2), suggesting that the currently developed CoMFA model achieves the predictive 
task for the novel synthesized compounds better. 
2.3. Contour Maps 
The CoMFA and CoMSIA results are represented as 3D coefficient contour maps which show 
regions  where  variations  of  different  fields  in  the  structural  features  of  the  molecules  lead  to  the 
increase or decrease of  the activity.  In this study  the most potent  compound 27 is exhibited as a 
representative molecule in the following CoMFA and CoMSIA contour maps (Figures 3 and 4). 
The steric and electrostatic fields from the best CoMFA model are represented in Figure 3. In the 
steric field (Figure 3A), the green-colored contours represent the regions of favorable steric effect, 
while yellow-colored contours represent regions of unfavorable steric effect, respectively. 
Figure  3.  CoMFA  StDev*Coeff  contour  plots  with  the  combination  of  compound  27.  
(A)  Steric  contour  map.  Green  contours  indicate  regions  where  bulky  groups  increase 
activity  (favored  level  80%);  yellow  contours  indicate  regions  where  bulky  groups 
decrease  activity  (disfavored  level  20%).  (B)  Electrostatic  contour  map.  Red  contours 
indicate  regions  where  negative  charges  increase  activity  (disfavored  level  20%);  blue 
contours indicate regions where positive charges increase activity (favored level 80%). 
 
As shown in Figure 3A, there exists a large green contour surrounding the cyclohexyl ring linked to 
the C5 position of the thiazole ring, indicating that the presence of a bulky group in this position will 
induce  an  increase  of  the  inhibition  activity  for  the  class  of  compounds.  The  observation  is  fully 
supported by the experimental results. For example, a comparison among C5-thiazole analogues with 
various  alkyl  groups  (molecules  18–27  shown  in  Supporting  Information,  Table  S4)  comes  to  a 
conclusion that the large substituent at 5-position on the thiazole core keeps optimal, since in this 
position the cyclohexyl ring falls into the green-colored zone. In addition, a careful inspection shows 
that a small yellow-colored map is located at the distal of the cyclohexyl ring, suggesting that too large 
groups are disfavored in this position. Taking compound 30, for example, insertion of a methylene 
group between the cyclohexyl ring and the thiazole core leads to a decrease of the activity, compared 
with its counterpart compound 27. By analyzing the docking simulation as discussed previously, it can Int. J. Mol. Sci. 2011, 12                       
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also be found that the distal carbon atom of the cyclohexyl core is near the side chain of Asp178 (with 
a distance of 2.8 Å in the binding pocket). Thus, one conclusion can be drawn that a proper size alkyl 
group is required at the C5 position to increase the inhibitory activity. 
Another large green-colored map situates at C2 position of the thiazole core, indicating the favor of 
a  large  substituent  group  for  enhancing  the  inhibitory  potency.  However,  at  the  back  of  this  
green-colored  contour,  a  yellow-colored  map  is  also  observed,  suggesting  the  careful  selection  of 
groups  of  proper  size  in  this  position.  This  investigation  is  also  consistent  with  the  experimental 
investigation, where for instance, compounds 2 and 3 with larger C2-groups such as ethyl and vinyl 
groups result in loss of potency compared to their counterpart, compound 1 having a methyl group at 
the C2 position of the thiazole core (Table S4). We also notice that if both the aryl and heteroaryl 
groups  are  introduced  to  the  C2  position,  the  potency  largely  decreases  that  it  is  much  lower  
(see compounds 15–17) than that of the molecule 1.  In  addition, an elimination of the C2-Me of 
compound 1 also leads to a 5-fold weaker compound in thiazole derivative 5, indicating that a suitable 
C2-group is important for the activity. Our previous investigation of the docking results also finds that 
the amino group attached to the C2 position of thiazole core forms two hydrogen bonds respectively 
with the side chain of Thr31 (with a bond length of 1.9 Å) and with the main chain of Val17 (with a 
bond length of 1.9 Å), which indicates that any larger substitute group might lead to a collision with 
these residues in the binding pocket, and thus the larger group here is forbidden. 
The CoMFA electrostatic contour map with the most potent compound 27 is shown in Figure 3B. 
Blue contour maps mean that positive-charged substituent groups are beneficial for the activity while 
red contours indicate that negative charges are conducive. As shown in Figure 3B, blue contour maps 
are observed surrounding the amino group at the C2 position of the thiazole core suggesting that a 
charge withdrawing group near these positions enhances the biological activity. The investigation is in 
agreement with previous docking results. As can be seen in Figure 1, the –NH2 group, as a hydrogen 
bond  donor,  can  interaction  with  both  Thr31  and  Val17.  In  addition,  one  can  also  notice  that 
substituent of the hydrogen atom with methyl group (compound 11) leads to a large loss of potency 
compared to compound 10 probably due to the lack of the hydrogen bond donor atom. In addition, a 
large red contour map exists around the phosphate group and embeds the cyclohexyl group illustrating 
that in these positions electro-rich groups are beneficial for increasing the activity. This may be a 
reason that all compounds of the dataset contain such electronegative groups (phosphate group). 
The CoMSIA steric and electrostatic contour maps (Figure 4A,B) are similar to the CoMFA model 
and thus are not discussed here additionally. Figure 4C depicts the H-bond acceptor contour map of the 
CoMSIA model. Magenta contours encompass areas where an H-bond acceptor leads to improved 
biological activity, while an acceptor located near the cyan regions results in the loss of biological 
activity. Clearly, it is easily found that a large magenta-colored map is surrounding the phosphate 
group and the cyclohexyl group, indicating the favor of the presence of H-bond acceptor groups in this 
region  for  the  activity.  The  investigation  is  also  supported  by  previous  CoMFA  and  CoMSIA 
electrostatic contour maps where, in these positions, a large red map exists, indicating electro-rich 
groups as hydrogen bond acceptors are beneficial to increase the potency of these inhibitors. Analysis 
of docking results also shows that the oxygen atoms of the phosphate group as hydrogen acceptors 
form six hydrogen bonds with the FBPase: two with the side chain hydroxyl groups of Thr27 and 
Tyr113 with the bond lengths of 2.3 and 1.8 Å respectively; three with the main chain amino groups of Int. J. Mol. Sci. 2011, 12                       
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Thr27, Glu29 and Lue30 with H-bond lengths of 1.9, 2.7and 1.9 Å, separately; and one with the side 
chain amino group of Lys112 with the bond length of 1.9 Å. The investigation also consists with the 
previous report [31]. In addition, a small cyan contour map is near the amino group at C2 position of 
the thiazole core, indicating the disfavored regions for H-bond acceptor groups. In fact, in the position, 
hydrogen bond donor groups are favored as depicted in CoMFA and CoMSIA electrostatic contour 
maps as well as the docking results. Thus this information obtained from the CoMFA and CoMSIA 
contour maps is helpful to understand the interactions between the inhibitors and the FBPase. 
Figure  4. CoMSIA StDev*Coeff contour plots with the combination of compound 27.  
(A)  Steric  contour  map.  Green  contours  indicate  regions  where  bulky  groups  increase 
activity  (favored  level  80%);  yellow  contours  indicate  regions  where  bulky  groups 
decrease  activity  (disfavored  level  20%).  (B)  Electrostatic  contour  map.  Red  contours 
indicate  regions  where  negative  charges  increase  activity  (disfavored  level  20%);  blue 
contours indicate regions where positive charges increase activity (favored level 80%). (C) 
H-bond acceptor contour map. Magenta contours indicate regions where H-bond acceptor 
substituents  increase  activity  (favored  level  85%);  cyan  contours  indicate  the  disfavor 
regions for H-bond acceptor groups (disfavored level 15%). 
 
Since  the  previous  report  [28]  is  the  subset  of  the  current  research,  it  is  very  interesting  to 
investigate  both  the  similarity  and  difference  between  them.  Firstly,  we  compare  the  external 
validation abilities of the best CoMFA models for Chen’s [28] and ours. The best CoMFA model 
developed by Chen et al. gives rpred
2 and rm
2 of 0.805 and 0.887, respectively, while, herein the present 
model exhibits the rpred
2 of 0.902, and rm
2 of 0.828. Apparently, both the discussed models present the 
comparable prediction performance. However, it should be noted that the former model was built 
based on the 63 compounds, while the latter was developed based on 105 molecules with the high 
statistical confidence. In addition, similar conclusions for modes of interaction between FBPase and Int. J. Mol. Sci. 2011, 12                       
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inhibitors based the 3D-QSAR models and docking experiments from Chen’s and ours are drawn 
depicted as follows: (1) At C5 position of the thiazole core, a substituent group with a proper length 
and size are beneficial to enhance the potency. (2) At C2 position in the thiazole ring, a small and  
electron-withdraw group is likely to helpful to increase the FBPase inhibition. (3) Substituent groups 
(such as phosphate) as hydrogen bond acceptors at the C2 position of the furan ring are favored.  
(4) Several important amino acid residues (such as Thr27, Glu29, Lys112, etc.) are identified to play a 
central role in the ligand binding. In summary, the findings made by Chen complement our findings 
and offer a clue to designing novel FBPase inhibitors. 
2.4. MD Simulations 
In  the  current  investigation,  a  7  ns  molecular  dynamics  simulation  of  the  docked  complex  of 
FBPase with inhibitor 27 was performed to obtain a dynamic picture of the conformational changes 
that occur in an aqueous solution, with main emphasis to explore the conformational change that takes 
place in the inhibitor and the enzyme (Figure 5). 
Figure 5A shows the RMSD of the trajectory for the complex with respect to the initial structure  
(in blue line), the graph presents that the RMSD reaches about 3.5 Å which suggests that a relatively 
stable  conformation  of  the  protein  is  achieved  through  the  MD  simulation.  Figure  5A  also  gives  
the RMSD of the ligand 27 (in red line) in the binding site of FBPase. It can be noted that the RMSD 
for the ligand reaches about 1.5 Å after 1 ns of MD simulation and retains this value throughout  
the simulation.  
In order to validate the reliability of the docking results, we have compared the results between the 
MD and docking simulations in terms of H-bond interactions and van der Waals contacts. By and large, 
the interaction modes produced between MD and docking simulations share the common features. For 
example, the phosphate of compound 27 forms three common H-bonds with residues of Thr27, Lys112 
and Tyr113. The amino group attached to the thiazole ring forms one common hydrogen bond with 
Val17. As for van der Waals interactions, both modes basically keep similar interactions. Furthermore, 
it can also be noticed that there exists slight differences among docking and MD simulation. For the 
MD results, the phosphate group presents two another H-bonds with residue of Arg140, and lacks the 
two H-bonds with residues of Glu29 and Leu30 that can be found in the docking results. In addition, 
the  loss  of  the  hydrogen  between  the  amino  group  attached  to  thiazole  and  the  residue  of  Thr31 
presented in the docking is compensated by the newly formed H-bond between –NH2 with residues of 
Met18, Glu20 and Arg25 during the MD simulation. 
In order to compare the structures from MD simulations and docking, a superimposition of both the 
structures  in  the  last  1  ns  is  shown  in  Figure  5B,  where  the  hotpink  ribbon  represents  the  initial 
structure for the docked complex, the forestgreen ribbon represents the average structure of the MD 
simulations, with compound 27 represented as stick and line for the initial complex and the average 
complex,  respectively.  It  can  be  noticed  that,  from  this  figure,  there  is  no  significant  difference 
between the average structure extracted from MD simulations and the docked model of the complex, 
except the cyclohexyl ring exhibiting 90° rotation. However, although the complex has undergone 
slight movements during MD simulation, both the binding pocket and the conformation of the ligand 
are still stable, suggesting the rationality and validity of the docking model. Int. J. Mol. Sci. 2011, 12                       
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Figure 5. (A) Plot of the root-mean-square deviation (RMSD) of docked complex/ligand 
versus the MD simulation time in the MD-simulated structures. (B) View of superimposed 
backbone atoms of the average structure of the last 1000 ps of the MD simulation (forest 
green) and the initial structure (hot pink) for inhibitor 27-FBPase complex. Compound 27 
is represented in yellow for the initial structure and blue for the final average complex. 
 
3. Materials and Experimental Methods 
3.1. Dataset 
A  large,  diverse  dataset  of  105  inhibitors  of  FBPase  were  collected  from  literatures  [38,39] 
published by Dang and co-workers. Here, the converted molar pIC50 (−log IC50) values, ranging from 
4.870 to 8.000 M, were used as the dependent variables in the QSAR regression analysis to improve 
the normal distribution of the experimental data points. The whole data set was divided into training 
(77 molecules) and test (28 molecules) sets, respectively. All structures and the corresponding activity 
values of the dataset as well as their belongings to the training or test set are listed in Table  S4 
(Supporting Information). Herein, the principle for selection of the test set chemicals was to ensure that, 
on one hand, their pIC50 values are randomly but uniformly distributed in the range of the values for 
the whole set, and on the other hand, their structures cover as large diversity as possible of the dataset 
so that the derived models could represent the real characteristics of all the compounds both from the 
biological activity and the structures. Int. J. Mol. Sci. 2011, 12                       
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3.2. Molecular Modeling and Alignment 
The 3D structures of all compounds were constructed by using the sketch molecule modules of 
SYBYL6.9 package. Partial atomic charges were calculated by Gasteiger-Hückel method, and energy 
minimizations  were  performed  by  using  the  Tripos  force  field  and  the  Powell  conjugate  gradient 
algorithm with a convergence criterion of 0.005 kcal/mol. 
Molecular alignment of compounds is a crucial step for the successful development of 3D-QSAR 
models [40]. Thus, in the present work, three alignment methods were performed. Alignment I: In this 
process, the most potent compound 27 was chosen as a template to fit the remaining training and test 
set of compounds. Thereafter, all compounds finally minimized with the lowest energy in the dataset 
were aligned to a common substructure (using the phosphate radical) by substructure-based alignment 
method using the “align database” command in SYBYL (Figure 6A). Alignment II: It is the alignment 
from the direct molecular docking conformations (Figure 6B). Alignment III: It is the combination of 
both alignments I and II, which means that the molecular active conformations are obtained from 
molecular docking, while using the same alignment method as that of alignment I. Figure 6C presents 
this alignment result. 
Figure  6.  The  alignment  of  all  molecules  in  the  dataset.  (A)  Database  alignment 
(Alignment I). (B) Alignment from the direct molecular docking conformations (Alignment II). 
(C) Alignment from the combination of both alignments I and II, which means that the 
molecular active conformations are obtained from molecular docking, while using the same 
alignment method as that of alignment I (Alignment III). 
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3.3. Docking Simulation 
Docking  simulations  of  thiazoles  and  oxazoles  analogs  into  the  FBPase  binding  pocket  were 
performed using the Surflex-dock module (V 2.51) of another advanced version of SYBYL package 
(X 1.1) in this study [41]. The docking method aligns the ligand to a “protomol” or idealized ligand in 
the active site of the target. The Surflex-dock algorithm and scoring functions have been reported in 
detail previously [42]. For our studies, the X-ray crystal structure of FBPase with high resolution  
(2.30 Å) was retrieved from RCSB Protein Data Bank (PDB entry code: 1FTA Chain A). Prior to 
docking, the ligand and other sub-structures were extracted from the crystal structure, and hydrogen 
atoms were added to the protein in standard geometry using the biopolymer modulators. In this study,  
Ligand-based Mode was adopted to generate the protomol in Surflex-dock program. Two adjustable 
parameters that affect the size and extend of the generated protomol are the threshold and the bloat 
values. In the present work, the threshold and bloat values were set to 0.5 and 0, respectively. Other 
parameters were adopted by default values in the Surflex-dock. In the current work, the maximum 
number of poses per ligand was set to ten. The conformations with the highest total scores for each 
ligand of the data set were aligned automatically together inside the binding pocket of FBPase and 
used directly for CoMFA and CoMSIA research. 
3.4. CoMFA and CoMSIA Interaction Energy Calculations 
The steric and electrostatic field energies were calculated using a sp
3 probe atom with a charge of 
+1.0 at all intersections of a regularly spaced grid of 2.0 Å in all three dimensions with the defined 
region. The van der Waals and Coulomb-type potentials representing the steric and electrostatic fields, 
respectively, were calculated using the Tripos force fields. The grid box dimensions were determined 
by the created automatically features in the CoMFA module within the SYBYL program. The steric 
and electrostatic energy values were both truncated to 30.0 kcal/mol. 
In  CoMSIA,  the  steric,  electrostatic,  hydrophobic,  hydrogen  bond  donor  and  hydrogen  bond 
acceptor potential fields were also calculated at each lattice intersection of a regularly spaced grid of 
2.0  Å  as  that  used  in  CoMFA.  A  probe  atom  with  radius  1.0  Å  and  a  charge  of  +1.0  with 
hydrophobicity  of  +1.0  and  dydrogen  bond  donor  and  acceptor  properties  of  +1.0  were  used  to 
estimate the steric, electrostatic, hydrophobic, donor and acceptor fields. The attenuation factor α was 
set to 0.3. CoMSIA similarity indices (AF) for a molecule j with atom i at a grid point q were calculated 
by equation (2): 
2
, , ) (
iq e j A ik k probe
q
k F
αγ ω ω
− ∑ − =   (2) 
where  k  represents  the  steric,  electrostatic,  hydrophobic,  or  hydrogen-bond  donor  or  acceptor 
descriptor. ωprobe,k is the probe atom with radius 1.0 Å, charge +1.0, hydrophobicity +1.0, H-bond 
donating +1.0, H-bond accepting +1.0; ωik is the actual value of the physicochemical property k of 
atom i; riq is the mutual distance between the probe atom at grid point q and atom i of the test molecule.  Int. J. Mol. Sci. 2011, 12                       
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3.5. Partial Lleast Square (PLS) Analysis and Statistical Validation 
In the current study, the CoMFA and CoMSIA descriptors served as independent variables and the 
active values (pIC50) as dependent variables in PLS regression analysis for building the 3D-QSAR 
models.  The  predictive  values  of  the  models  were  evaluated  first  by  leave-one-out  (LOO)  
cross-validation process [43,44]. The cross-validated coefficient, q
2, was calculated using equation (3): 
2
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q   (3) 
where  i y ,  i y ˆ , and  tr y  are the observed, predicted, and mean values of the target property (pIC50), 
respectively  for  the  training  set.  Herein,  the  term, 
2
1
) ˆ ( ∑
=
−
train
i
i i y y ,  is  the  predictive  residual  sum  of 
squares (PRESS). The optimal number of components obtained from the cross-validation was used to 
derive the final QSAR model. Then, a non-cross-validation analysis was carried out; and the Pearson 
coefficient (rncv
2), standard error of estimates (SEE) and the F values were calculated. Finally, the 
CoMFA  and  CoMSIA  results  were  graphically  represented  by  field  contour  maps,  where  the 
coefficients were generated using the field type “Stdev*Coeff”. 
As been reported [32], although the low value of q
2 for the training set can exhibit a low predictive 
ability  of  a  model,  the  opposite  is  not  necessarily  true.  That  is,  the  high  q
2  is  necessary,  but  not 
sufficient, for  a model  with the high predictive power. Therefore, the  external validation must be 
estimated to establish a reliable and predictive QSAR model. Several often used statistical criteria are 
listed as follows: 
5 . 0
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  (6) 
15 . 1 85 . 0 ≤ ≤ k   (7) 
In equation (4), the predictive r
2, rpred
2, is defined as follow: 
) / " (" 1
2 SD PRESS rpred − =   (8) 
where SD is the sum of the squared deviations between the actual activity of the compounds in the test 
set and the mean activity in the training set, and “PRESS” is the sum of the squared deviations between 
predicted  and  observed  activity  for  each  compound  in  the  test  set.  In  equation  (4),  rtest
2  is  the 
conventional correlation coefficient between experimental values and model predictions in the test set. 
The r0
2 is a quantity characterizing linear regression with the Y-intercept set to zero (i.e., described by 
Y = kX, where Y and X are the actual and predictive activity, respectively). The k in equation (6) is the 
slope of regression lines (predicted versus observed activities) through the origin. The definitions of 
the afore-mentioned statistical indices are reported in detail in references [32–35]. Int. J. Mol. Sci. 2011, 12                       
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3.6. Molecular Dynamics Simulations 
To identify a functionally validated complex from protein docking and the most potent molecule 27, 
we performed 5 ns molecular dynamics simulations to investigate the conformational changes in the 
complex induced by the ligand 27. The software AMBER 11 [45] was used for the MD simulations. 
The inhibitors were minimized using the HF/6-31G* optimization in Gaussian03 [46], and the atom 
partial charges were obtained by fitting the electrostatic potentials derived by Gaussian via the RESP 
fitting technique in AMBER 11. The force field parameters for these molecules were assigned by the 
Antechamber program [47] in AMBER 11. Hydrogen atoms were added to the protein with Tleap 
module from AMBER. The system was then put in to a rectangular box of TIP3P water molecules [48], 
and this solvated system contained approximate 59,365 atoms. 
The whole systems were minimized in three stages to remove bad contacts between the complex 
and the solvent molecules. Firstly, the water molecules were minimized by restraining the protein; 
Secondly, water and the side chains of the protein were minimized by restraining the backbone of the 
protein,  and  each  stage  was  performed  by  using  the  steepest  descent  minimization  of  2500  steps 
followed  by  a  conjugate  gradient  minimization  of  2500  steps.  Thirdly,  the  entire  system  was 
minimized without any restriction by 10,000 steps changing the minimization method from steepest 
descent to conjugate gradient after 5000 cycles. After 15,000 steps minimization and equilibration for 
60 ps, the system was then heated gradually from 0 to 310 K in the NVT ensemble and equilibrated at 
310 K for another 60 ps. After the minimization and heating, 5 ns MD simulations were performed at a 
constant temperature of 310 K and a constant pressure of 1 atm. The Particle-Mesh Ewald (PME) 
method [49] was employed to deal with the long-range electrostatic interactions [50] in a periodic 
boundary  condition.  The  SHAKE  algorithm  [51]  was  applied  to  fix  all  bond  lengths  involving 
hydrogen bonds, permitting a 2-fs time step. 
4. Conclusions 
Presently, a large dataset of 105 thiazoles and oxazoles derivatives as potent orally bioavailable 
FBPase inhibitors for lowing glucose in type 2 diabetes mellitus has been estimated for the purpose of 
developing  3D-QSAR  models  based  on  both  the  ligand-  and  receptor-based  superimpositions. 
Statistically  significant  models  have  been  derived  with  two  3D-QSAR  methods  of  CoMFA  and 
CoMSIA  on  the  basis  of  the  database  alignment  method.  The  CoMFA  model  presents  higher 
predictivity than CoMSIA expressed in terms of several rigorous evaluation criteria such as q
2, rpred
2 
and rm
2 for both the internal and external data sets. In addition, both of the two methods pass the  
y-randomization check, suggesting the robustness of the built models. Graphical interpretation of the 
optimal results, provided by the CoMFA and CoMSIA analyses, brings to light the important structural 
features that could be responsible for the activity of FBPase inhibitors. (i) Substituents with a proper 
length and size at the C5 position of the thiazole core are required to enhance the potency; (ii) A small 
and electron-withdraw group at the C2 position linked to the thiazole core is likely to help to increase 
the FBPase inhibition; (iii) Substituent groups as hydrogen bond acceptors at the C2 position of the 
furan ring are favored; (iv) Furthermore, the key amino residues have been found, i.e., Leu30, Glu29, 
Lys113, Lys112 and Thr27 which form the important hydrogen bond network with the phosphate Int. J. Mol. Sci. 2011, 12                       
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group of FBPase, and Thr31, Val17 also play an important role in the binding between the ligand and 
the target. 
In addition, a good consistency between the CoMFA and CoMSIA contour maps, molecular docking 
and molecular dynamics simulations proves the reliability and robustness of the developed models. 
Overall, in this report, several reliable computation models between thiazole/oxazole analogues and 
FBPase have been built, which not only exhibit satisfied statistics, but also provide several possible 
mechanism interpretations from a molecular-level. We hope the models may provide some instructions 
for further synthesis of highly potent FBPase inhibitors. 
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